(R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester | 122536-68-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester
• 英文别名: (R)-benzyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate；benzyl (3R)-3-(methanesulfonyloxy)pyrrolidine-1-carboxylate；benzyl (3R)-3-[(methylsulfonyl)oxy]-1-pyrrolidinecarboxylate；(R)-1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate；benzyl (3R)-3-methylsulfonyloxypyrrolidine-1-carboxylate
• CAS: 122536-68-9
• 化学式: C₁₃H₁₇NO₅S
• 分子量: 299.348
• InChiKey: LNRBIPMUYLVQFG-GFCCVEGCSA-N

物化性质

• 沸点：
  481.6±44.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester 在 盐酸 、 水 、 磺酰胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 50.5h， 生成 benzyl (3S)-3-(dimethylcarbamoyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY
  [FR] AGENTS ANTIBACTÉRIENS DE CARBAPÉNEM AVEC ACTIVITÉ ANTI-GRAM NÉGATIF

  摘要：

  公开号：

  WO2011160020A3
• 作为产物：
  描述：

  氯甲酸苄酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 (R)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS
  [FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DE LA TYROSINE KINASE BCR-ABL

  摘要：

  揭示了一种式（Ⅰ）的化合物或其药学上可接受的盐，其中所述的变量在此处描述。还揭示了一种制备化合物的方法，其药用组合物包括作为活性成分的相同化合物，使用这些组合物治疗各种疾病的方法，以及利用这些化合物制造药物以抑制ABL1、ABL2和相关嵌合蛋白的酶活性。

  公开号：

  WO2017186148A1

文献信息

• [EN] PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS<br/>[FR] LIGANDS DE RECEPTEURS HISTAMINIQUES A BASE DE DERIVES PYRROLIDINIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2006040192A1

  公开（公告）日：2006-04-20

  The present invention relates to pyrrolidine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的吡咯烷衍生物公式(I)，它们的制备方法，含有它们的组合物及其在治疗神经和精神障碍中的用途。
• (S)-7-(3-amino-1-pyrrolidinyl)-1-cyclop
  申请人：Warner-Lambert Company

  公开号：US04916141A1

  公开（公告）日：1990-04-10

  The novel (S)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1, 8-n phthyridine-3-carboxylic acid, lower alkyl esters and pharmaceutically acceptable salts thereof are described as well as a method for its manufacture, formulation, and use in treating bacterial infections.

  本文介绍了一种小说(S)-7-(3-氨基-1-吡咯烷基)-1-环丙基-6-氟-1,4-二氢-4-氧-1,8-萘啶-3-羧酸，其低烷基酯和药学上可接受的盐，以及其制造、配方和用于治疗细菌感染的方法。
• Naphthyridine antibacterial agents containing an .alpha.-amino acid in
  申请人：Warner-Lambert Company

  公开号：US04851418A1

  公开（公告）日：1989-07-25

  Novel quinolone and naphthyridine antibacterial agents are herein described having improved in vivo activity both orally and subcutaneously where the 7-side chain of such compounds contain an .alpha.-amino acid; also described are its corresponding optical isomers, methods of preparation as well as compositions and methods of treating infections diseases.

  本文描述了一种新型的喹诺酮和萘啶类抗菌剂，其具有口服和皮下注射的改善体内活性，其中这些化合物的7侧链包含一种α-氨基酸。同时还描述了其相应的光学异构体、制备方法以及治疗感染性疾病的组合物和方法。
• Pyrrolidine Derivatives as Histamine Receptors Ligands
  申请人：Bruton Gordon

  公开号：US20080045506A1

  公开（公告）日：2008-02-21

  The present invention relates to pyrrolidine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的公式（I）的吡咯烷衍生物，其制备过程，包含它们的组合物以及它们在治疗神经系统和精神疾病中的应用。
• Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity
  作者：Joseph P. Sanchez、John M. Domagala、Carl L. Heifetz、Stephen R. Priebe、Josephine A. Sesnie、Ashok K. Trehan

  DOI：10.1021/jm00088a011

  日期：1992.5

  A series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)-6-fluoro-1,8-naphthyridine-3-carboxylic acids, 1-cyclopropyl-6,8-difluoro-3-quinolinecarboxylic acids, 1-cyclopropyl-6-fluoro-3-quinolinecarboxylic acids, and 5-amino-1-cyclopropyl-6,8-difluoro-3-quinolinecarboxylic acids have been prepared and evaluated for comparative antibacterial activity. Compounds were prepared by acylation of the 3-amino group of the pyrrolidine with common amino acids using standard peptide chemistry. This series has been compared with the parent compounds for antibacterial activity in vitro and in vivo as well as for comparatively solubility. The amino acid analogues were less active in vitro, but had equal or increased efficacy in vivo. Indeed, it was proven that these compounds, which were stable to acid and base under the reaction conditions for their preparation, were rapidly cleaved in serum to give the parent quinolones. The amino acid derivatives showed a 3-70 times improved solubility when compared to the parent compounds. The most active compound of the series was [S-(R*,R*)]-7-[3-[2-amino-1-oxopropyl)-amino]-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (PD 131112).